JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
209,65 $
arrow_downward
-0,35%(-0,74) 1D
209,65 $
0,00% (0,00)
bedtimeAfter hours
Closed: 14 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for JAZZ...
Open
210,34 $
High
215,66 $
Low
209,36 $
Mkt. cap
13,61 մլրդ
Avg. vol.
791,77 հզր
Volume
891,56 հզր
P/E ratio
14,33
52-wk high
266,38 $
52-wk low
128,80 $
EPS
14,63 $
Beta
0,37
Shares outstanding
64,92 մլն
No. of employees
3 հզր
Open
210,34 $
High
215,66 $
Low
209,36 $
Mkt. cap
13,61 մլրդ
Avg. vol.
791,77 հզր
Volume
891,56 հզր
P/E ratio
14,33
52-wk high
266,38 $
52-wk low
128,80 $
EPS
14,63 $
Beta
0,37
Shares outstanding
64,92 մլն
No. of employees
3 հզր
News stories
From web sources and news partners
Benzinga
·
2 օր առաջ
Jim Cramer Gives Green Light To This Health Care Stock
https://www.dars.gov.et/
·
2 ամիս առաջ
Jazz Pharmaceuticals (JAZZ) Holds Steady at $256.52 as Shares Trade Flat - FRAMA Signal
Profile
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC